Rush Researchers Investigating Autoantibodies for Ovarian Cancer Risk Screening and Diagnosis | GenomeWeb

By Adam Bonislawski

Researchers at Rush University Medical Center are exploring the use of autoantibodies as protein biomarkers for identifying women at increased risk of developing ovarian cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.